What Are the Cannabis Licensing Requirements in Virginia? (2026)

Virginia has enacted a framework for licensed adult-use cannabis sales, with the retail launch scheduled for July 1, 2027. Businesses should distinguish that forthcoming market from the existing medical cannabis program and from personal possession and home cultivation. Adult-use retail sales did not begin in July 2024.

The Virginia Cannabis Control Authority (CCA) oversees cannabis licensing. It assumed medical cannabis oversight on January 1, 2024, so old instructions directing pharmaceutical processor applicants to the Board of Pharmacy are no longer the correct starting point.

Adult-Use Licensing: The Current Implementation Timeline

The CCA’s retail market implementation page identifies these milestones:

• September 2026: initial draft regulations.
• October–December 2026: public health advisory review and finalization of regulations.
• January 2027: regulations published and effective.
• By February 1, 2027: conversion applications for pharmaceutical processors and eligible industrial hemp processors or growers, plus the application process for some microbusiness licenses.
• By May 1, 2027: issuance of certain initial licenses.
• July 1, 2027: retail marijuana sales begin.

The listed categories are cultivation, processing, testing laboratory, transporter, delivery operator, retail store, dual use, and microbusiness. A draft rule or a statutory license category does not mean applications for that category are open. Use CCA’s final instructions for eligibility, documentation, fees, and filing dates.

Cultivation Licenses and Impact Applicants

The enacted cultivation framework uses five tiers rather than the older Class A/Class B description:

• Tier I: up to 5,000 square feet of canopy, indoors or outdoors.
• Tier II: up to 10,000 square feet, indoors or outdoors.
• Tier III: up to 15,000 square feet, indoors.
• Tier IV: up to 25,000 square feet, indoors.
• Tier V: up to 35,000 square feet, indoors.

The law also addresses Board adjustments, secure greenhouses, outdoor-site restrictions, and tracking. These are commercial licensing provisions; they do not increase a household’s personal plant allowance.

Under § 4.1-606, an impact applicant must have at least 51% ownership and direct control by qualifying people. Those owners must meet the specified residence test involving a disproportionately policed jurisdiction or a historically economically disadvantaged community, and at least one additional criterion. The latter include specified marijuana convictions or family relationships, qualifying education or Pell Grant history, military veteran status, or qualifying USDA distressed-farmer assistance.

The residence and additional criteria work together; military service or an education credential alone does not establish eligibility. CCA must implement the application preferences and assistance provisions. Applicants should document their actual ownership, control, and qualifying history instead of relying on the former 66% social equity summary.

Medical Cannabis Business Permits

The existing medical program uses pharmaceutical processor permits and associated dispensing facilities. The CCA’s processor page explains that applications are accepted only during a Notice of Open Application period. The process includes an initial application, scoring and review, conditional approval, and a final permit. A past application announcement is not a standing opportunity to submit.

§ 4.1-1602 limits processor permits to one per health service area and provides for up to five associated dispensing facilities in each area. Material owners undergo fingerprint-based background checks. The program requires pharmacist oversight of dispensing, security, testing, records, and compliant labeling. Current processor cultivation is indoors, including qualifying secure greenhouses, with an aggregate canopy limit of 70,000 square feet.

Existing processors also have a transition requirement: from June 1, 2027, previously issued permits do not remain valid without the required dual-use verification. Dual-use privileges require an application, conversion fee, and Board verification; holding a medical permit does not automatically authorize adult-use sales.

Medical Permit Costs and Patient Access

The current pharmaceutical processor fee regulation sets an $18,000 application fee, $165,000 initial permit fee, and $132,000 annual renewal fee. Additional charges apply to certain changes, inspections, and product registrations. These are medical processor fees, not a price list for the forthcoming adult-use licenses.

Patients do not need a terminal illness to qualify. An eligible practitioner determines whether a condition or disease may benefit from cannabis. Patients need a valid written certification and government-issued identification, with evidence of Virginia residency where necessary. CCA’s patient instructions explain the process for adults, minors, and caregivers.

Separate patient registration is not required to purchase from licensed dispensaries, according to CCA’s FAQ.

Personal Cultivation and Hemp Are Separate Routes

Adults aged 21 or older may grow no more than four plants per household for personal use. Plants must be kept out of public view, protected from access by people under 21, and tagged with the required identifying information and personal-use statement. These home cultivation rules do not permit a household to sell its harvest.

The current personal possession allowance outside a private residence is two ounces for adults 21 or older. Paid transactions disguised as gifts remain prohibited. See our Virginia cannabis law guide for the broader personal-use context.

Hemp retail registration also does not authorize marijuana sales. Virginia’s 2026 hemp changes moved regulated hemp-product oversight to CCA and ended the 25:1 CBD-to-THC exception on August 15. Products sold as hemp must meet the 0.3% total THC and two-milligram-per-package limits. VDACS continues to handle industrial hemp grower, processor, and handler registrations. Our Virginia CBD guide covers this distinct product category.